Fingolimod Therapy for Pediatric Relapsing-Remitting Multiple Sclerosis: A Real-Life Study
Journal Title: Turkish Journal of Neurology - Year 2020, Vol 26, Issue 1
Abstract
Objective: Clinical studies in childhood multiple sclerosis (MS) are very limited compared with adults. Although first-line injection therapies are well tolerated in this patient group, there are difficulties in the long-term treatment of patients due to the difficulty and adverse effects of injections for children. Oral therapies are better tolerated for use and adverse effects compared with injection therapies. This study aimed to evaluate the clinical features and treatment outcomes of patients aged under 18 years with relapsing-remitting MS (RRMS) who received fingolimod treatment. Materials and Methods: In this study, the clinical records of 22 patients with RRMS who received fingolimod treatment were examined. The patients were prospectively followed up between February 2015 and December 2018. The patients were evaluated in terms of relapse rate, Expanded Disability Status Scale (EDSS) scores, brain and cervical magnetic resonance imaging, and adverse effects before and after fingolimod treatment. Results: The median age of 13 (59%) female and 9 (41%) male patients was 18 (range: 10-21) years. The median fingolimod treatment duration was 2.5 (range: 1.3-3.9) years. The median age of disease onset was 13 (range: 8-17) years. Fifteen patients (68%) received a first-line treatment prior to fingolimod. The reason for switching to fingolimod was inefficacy in 33%, adverse effects in 40%, and both in %27 of patients. In 32% of patients, fingolimod was started as a first-line treatment. A total of three patients had recurrent relapses under treatment with fingolimod. The median annualized relapse rate (ARR) before fingolimod was 1.9 (range: 0.3-8.0), and the ARR with fingolimod was 0 (range: 0-2.0) (Wilcoxon’s signed-rank test; p<0.001). The median EDSS was 1.5 (range: 1.0-4.0) before fingolimod, and the EDSS after treatment was 1.5 (range: 1.0 to 5.0) (Wilcoxon’s signed rank test; p=0.3). None of the patients had any adverse effects during the first dose monitoring. Conclusion: Our study shows that fingolimod is an effective and safe treatment alternative in childhood MS.
Authors and Affiliations
Canan Duman İlki, Tuncay Gündüz, Murat Kürtüncü, Zuhal Yapıcı, Serra Sencer, Mefküre Eraksoy
Keywords
Related Articles
- EP ID EP685128
- DOI 10.4274/tnd.2019.77010
- Views 193
- Downloads 0
Acquired Immune Deficiency Syndrome Showing Its First Symptom with Nervous System Involvement
Human immunodeficiency virus (HIV) infection is increasingly common today and the diversity of its clinical presentation makes the diagnosis difficult. The virus can cause neurologic involvement in the entire nervous sys...
Neurofibromatosis Type 1-related Multiple Plexiform Neurofibromas: A Case Report
Neurofibromatosis type 1 (NF1) and type 2 (NF2) are autosomal dominant diseases. Patients with NF1 or NF2 have the potential to develop benign and malignant tumors. We present a 17-year-old patient with undiagnosed NF1-r...
Reliability and Validity of the Turkish Version of the Mini-BESTest Balance Scale in Patients with Stroke
Objective: To determine the validity and reliability of the Turkish version of the Mini-BESTest balance scale (Mini-BESTest-Turk) and provide a culturally adapted version for use in Turkish patients with stroke. Materia...
The COVID-19 from Neurological Overview
No summary
An Unusual Case of Footdrop: Bilateral Common Peroneal Nerve Palsy by One Bullet Gunshot Injury
Common peroneal nerve injuries represent the most common nerve lesions of the lower limbs. Peroneal palsy might be due to traumatic origin. However, bilateral peroneal nerve involvement in an injury is rarely seen in cli...